279 related articles for article (PubMed ID: 34400057)
1. COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.
Chen YW; Tucker MD; Beckermann KE; Iams WT; Rini BI; Johnson DB
Eur J Cancer; 2021 Sep; 155():291-293. PubMed ID: 34400057
[No Abstract] [Full Text] [Related]
2. COVID-19 vaccination and cancer immunotherapy: should they stick together?
Brest P; Mograbi B; Hofman P; Milano G
Br J Cancer; 2022 Jan; 126(1):1-3. PubMed ID: 34799696
[TBL] [Abstract][Full Text] [Related]
3. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
Malek AE; Cornejo PP; Daoud N; Alam M
Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
[No Abstract] [Full Text] [Related]
4. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
[TBL] [Abstract][Full Text] [Related]
5. CureVac COVID vaccine let-down spotlights mRNA design challenges.
Dolgin E
Nature; 2021 Jun; 594(7864):483. PubMed ID: 34145413
[No Abstract] [Full Text] [Related]
6. How COVID unlocked the power of RNA vaccines.
Dolgin E
Nature; 2021 Jan; 589(7841):189-191. PubMed ID: 33437061
[No Abstract] [Full Text] [Related]
7. Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy.
Soeiro T; Salvo F; Pariente A; Grandvuillemin A; Jonville-Béra AP; Micallef J
Therapie; 2021; 76(4):365-367. PubMed ID: 33858693
[No Abstract] [Full Text] [Related]
8. Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients.
Bloomfield M; Parackova Z; Hanzlikova J; Lastovicka J; Sediva A
J Clin Immunol; 2022 Feb; 42(2):266-269. PubMed ID: 34718945
[No Abstract] [Full Text] [Related]
9. COVID-19 vaccination in Israel.
Muhsen K; Cohen D
Clin Microbiol Infect; 2021 Nov; 27(11):1570-1574. PubMed ID: 34384875
[No Abstract] [Full Text] [Related]
10. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.
Pascolo S
Viruses; 2021 Feb; 13(2):. PubMed ID: 33572452
[TBL] [Abstract][Full Text] [Related]
11. Maintaining Safety with SARS-CoV-2 Vaccines.
Castells MC; Phillips EJ
N Engl J Med; 2021 Feb; 384(7):643-649. PubMed ID: 33378605
[No Abstract] [Full Text] [Related]
12. Herpes zoster emergence following mRNA COVID-19 vaccine.
Eid E; Abdullah L; Kurban M; Abbas O
J Med Virol; 2021 Sep; 93(9):5231-5232. PubMed ID: 33913545
[No Abstract] [Full Text] [Related]
13. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
[No Abstract] [Full Text] [Related]
14. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.
Waissengrin B; Agbarya A; Safadi E; Padova H; Wolf I
Lancet Oncol; 2021 May; 22(5):581-583. PubMed ID: 33812495
[No Abstract] [Full Text] [Related]
15. Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms.
Heymans S; Cooper LT
Nat Rev Cardiol; 2022 Feb; 19(2):75-77. PubMed ID: 34887571
[TBL] [Abstract][Full Text] [Related]
16. Could mixing COVID vaccines boost immune response?
Ledford H
Nature; 2021 Feb; 590(7846):375-376. PubMed ID: 33547431
[No Abstract] [Full Text] [Related]
17. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
Strobel SB; Machiraju D; Kälber KA; Hassel JC
Cancer Immunol Immunother; 2022 Aug; 71(8):2051-2056. PubMed ID: 34940894
[TBL] [Abstract][Full Text] [Related]
18. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049
[TBL] [Abstract][Full Text] [Related]
19. Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan.
Sato T; Kodama S; Kaneko K; Imai J; Katagiri H
Emerg Infect Dis; 2022 Jul; 28(7):1518-1520. PubMed ID: 35468049
[TBL] [Abstract][Full Text] [Related]
20. Reflections on SARS-CoV-2 new strain contagiousness and its prevention with mRNA vaccines.
García-Vigil JL; García-Alvarez JL
Gac Med Mex; 2021; 157(3):318. PubMed ID: 34667321
[No Abstract] [Full Text] [Related]
[Next] [New Search]
